Sean Bohen, MD, PhD
Durvalumab (Imfinzi) significantly improved overall survival (OS) versus placebo when used as a sequential treatment in patients with locally-advanced, unresectable non–small cell lung cancer (NSCLC) who had not progressed following standard chemoradiotherapy, according to updated findings from the phase III PACIFIC trial.
<.001). Of the patients who had a response to durvalumab, 72.8% had an ongoing response at both 12 and 18 months as compared with 56.1% and 46.8%, respectively, in the placebo arm.
... to read the full story